SI2776442T1 - Derivati (1,2,3)triazolo(4,5-d)pirimidina kot agonisti kanabinoidnega receptorja 2 - Google Patents
Derivati (1,2,3)triazolo(4,5-d)pirimidina kot agonisti kanabinoidnega receptorja 2Info
- Publication number
- SI2776442T1 SI2776442T1 SI201230368T SI201230368T SI2776442T1 SI 2776442 T1 SI2776442 T1 SI 2776442T1 SI 201230368 T SI201230368 T SI 201230368T SI 201230368 T SI201230368 T SI 201230368T SI 2776442 T1 SI2776442 T1 SI 2776442T1
- Authority
- SI
- Slovenia
- Prior art keywords
- triazolo
- agonists
- pyrimidine derivatives
- cannabinoid receptor
- cannabinoid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11188333 | 2011-11-08 | ||
EP12780208.0A EP2776442B1 (en) | 2011-11-08 | 2012-11-05 | [1, 2, 3]triazolo [4, 5 -d]pyrimidine derivatives as agonists of the cannabinoid receptor 2 |
PCT/EP2012/071788 WO2013068306A1 (en) | 2011-11-08 | 2012-11-05 | [1, 2, 3] triazolo [4, 5 -d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2776442T1 true SI2776442T1 (sl) | 2015-12-31 |
Family
ID=47116003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201230368T SI2776442T1 (sl) | 2011-11-08 | 2012-11-05 | Derivati (1,2,3)triazolo(4,5-d)pirimidina kot agonisti kanabinoidnega receptorja 2 |
Country Status (31)
Country | Link |
---|---|
US (2) | US8741906B2 (sl) |
EP (1) | EP2776442B1 (sl) |
JP (1) | JP6138141B2 (sl) |
KR (1) | KR102032337B1 (sl) |
CN (1) | CN103930426B (sl) |
AR (1) | AR088663A1 (sl) |
AU (1) | AU2012334173B2 (sl) |
BR (1) | BR112014011055B1 (sl) |
CA (1) | CA2850458C (sl) |
CL (1) | CL2014001174A1 (sl) |
CO (1) | CO6920295A2 (sl) |
CY (1) | CY1117147T1 (sl) |
DK (1) | DK2776442T3 (sl) |
EA (1) | EA023581B1 (sl) |
ES (1) | ES2553704T3 (sl) |
HK (1) | HK1194732A1 (sl) |
HR (1) | HRP20160052T1 (sl) |
HU (1) | HUE025543T2 (sl) |
IL (1) | IL231949A (sl) |
MX (1) | MX342309B (sl) |
MY (1) | MY170878A (sl) |
PE (1) | PE20141588A1 (sl) |
PL (1) | PL2776442T3 (sl) |
PT (1) | PT2776442E (sl) |
RS (1) | RS54436B1 (sl) |
SG (1) | SG11201402197UA (sl) |
SI (1) | SI2776442T1 (sl) |
TW (2) | TWI704150B (sl) |
UA (1) | UA111640C2 (sl) |
WO (1) | WO2013068306A1 (sl) |
ZA (1) | ZA201402905B (sl) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA111640C2 (uk) * | 2011-11-08 | 2016-05-25 | Ф. Хоффманн-Ля Рош Аг | ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2 |
US9067943B2 (en) * | 2011-11-25 | 2015-06-30 | Hoffmann-La Roche Inc. | [1,2,3]triazolo[4,5-D]pyrimidine derivatives |
MA38403A1 (fr) | 2013-03-07 | 2017-11-30 | Hoffmann La Roche | Nouveaux dérivés de pyrazole modulateurs specifiques de cb2 |
PL2978755T3 (pl) | 2013-03-26 | 2018-05-30 | Hoffmann La Roche | Nowe pochodne pirydyny |
TR201809417T4 (tr) | 2013-05-02 | 2018-07-23 | Hoffmann La Roche | Cb2 reseptör agonistleri olarak purin türevleri. |
CA2907691A1 (en) | 2013-05-02 | 2014-11-06 | F. Hoffmann-La Roche Ag | Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists |
PT3041843T (pt) * | 2013-09-06 | 2019-02-26 | Hoffmann La Roche | Derivados de triazolo[4,5-d]pirimidina como agonistas do recetor cb2 |
PE20170682A1 (es) | 2014-08-04 | 2017-06-15 | Nuevolution As | Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados utiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncologicas y autoinmunitarias |
MX2017005857A (es) * | 2014-11-07 | 2017-06-26 | Hoffmann La Roche | Triazolo[4,5-d]pirimidinas como agonistas del receptor canabinoide 2. |
EP3294745B1 (en) * | 2015-05-08 | 2020-01-01 | H. Hoffnabb-La Roche Ag | Novel oxathiolane carboxylic acids and derivatives for the treatment and prophylaxis of virus infection |
CN105541738B (zh) * | 2016-01-21 | 2018-04-06 | 西北师范大学 | 一种三氮唑取代的苯乙酮类化合物的制备方法 |
WO2018015088A1 (en) | 2016-06-23 | 2018-01-25 | F. Hoffmann-La Roche Ag | Novel [1,2,31triazolo[4,5-d]pyrimidine derivatives |
MX2018014684A (es) * | 2016-06-23 | 2019-02-28 | Hoffmann La Roche | Derivados de [1,2,3]triazolo[4,5-d]pirimidina con afinidad para el receptor de canabinoide de tipo 2. |
WO2017220516A1 (en) | 2016-06-23 | 2017-12-28 | F. Hoffmann-La Roche Ag | Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives |
WO2017220544A1 (en) | 2016-06-23 | 2017-12-28 | F. Hoffmann-La Roche Ag | Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives |
WO2022011171A1 (en) * | 2020-07-08 | 2022-01-13 | Klotho Therapeutics, Inc. | Novel compounds and methods for increasing klotho gene expression |
JP2021535201A (ja) * | 2018-08-20 | 2021-12-16 | ベッソール ファルマ、エルエルシー | カンナビノイドの作成のためのプロセス |
CN113874377A (zh) | 2019-05-13 | 2021-12-31 | 埃科莱布美国股份有限公司 | 作为铜腐蚀抑制剂的1,2,4-三唑并[1,5-a]嘧啶衍生物 |
US11447479B2 (en) | 2019-12-20 | 2022-09-20 | Nuevolution A/S | Compounds active towards nuclear receptors |
WO2021198955A1 (en) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Compounds active towards nuclear receptors |
JP2023519605A (ja) | 2020-03-31 | 2023-05-11 | ヌエヴォリューション・アクティーゼルスカブ | 核内受容体に対して活性な化合物 |
CA3193762A1 (en) | 2020-11-23 | 2022-05-27 | F. Hoffmann-La Roche Ag | New process for the manufacture of tetrazole derivatives |
AR127456A1 (es) | 2021-10-28 | 2024-01-24 | Hoffmann La Roche | Sintesis de [1,2,3]triazol[4,5-d]pirimidinas |
WO2023237460A1 (en) | 2022-06-07 | 2023-12-14 | F. Hoffmann-La Roche Ag | A process for preparing 1-[5-tert-butyl-3-[(1-methyltetrazol-5 -yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol |
WO2024047078A1 (en) * | 2022-09-01 | 2024-03-07 | F. Hoffmann-La Roche Ag | Dosage regimen of vicasinabin |
WO2024047079A1 (en) | 2022-09-01 | 2024-03-07 | F. Hoffmann-La Roche Ag | Anti-cb2 antibodies and their use in a flow cytometry assay to measure cell surface cb2 expression |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4076711A (en) * | 1976-04-05 | 1978-02-28 | Schering Corporation | Triazolo [4,5-d]-pyrimidines |
US5204353A (en) * | 1987-04-07 | 1993-04-20 | Ciba-Geigy Corporation | 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith |
EP0723533A1 (en) * | 1993-10-12 | 1996-07-31 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
CN1142817A (zh) * | 1993-10-12 | 1997-02-12 | 杜邦麦克制药有限公司 | 1n-烷基-n-芳基嘧啶胺及其衍生物 |
EP2094705B1 (en) | 2006-12-14 | 2012-04-18 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
US7655685B2 (en) | 2007-11-02 | 2010-02-02 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
EP2219646A4 (en) | 2007-12-21 | 2010-12-22 | Univ Rochester | METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS |
CA2717509A1 (en) * | 2008-03-03 | 2009-09-11 | Tiger Pharmatech | Tyrosine kinase inhibitors |
AR080711A1 (es) * | 2010-03-31 | 2012-05-02 | Lilly Co Eli | Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor |
UA111640C2 (uk) * | 2011-11-08 | 2016-05-25 | Ф. Хоффманн-Ля Рош Аг | ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2 |
US9067943B2 (en) * | 2011-11-25 | 2015-06-30 | Hoffmann-La Roche Inc. | [1,2,3]triazolo[4,5-D]pyrimidine derivatives |
-
2012
- 2012-05-11 UA UAA201406094A patent/UA111640C2/uk unknown
- 2012-11-05 PE PE2014000649A patent/PE20141588A1/es active IP Right Grant
- 2012-11-05 WO PCT/EP2012/071788 patent/WO2013068306A1/en active Application Filing
- 2012-11-05 MY MYPI2014701156A patent/MY170878A/en unknown
- 2012-11-05 SG SG11201402197UA patent/SG11201402197UA/en unknown
- 2012-11-05 ES ES12780208T patent/ES2553704T3/es active Active
- 2012-11-05 RS RS20150807A patent/RS54436B1/en unknown
- 2012-11-05 EA EA201490912A patent/EA023581B1/ru unknown
- 2012-11-05 BR BR112014011055-7A patent/BR112014011055B1/pt active IP Right Grant
- 2012-11-05 SI SI201230368T patent/SI2776442T1/sl unknown
- 2012-11-05 PT PT127802080T patent/PT2776442E/pt unknown
- 2012-11-05 CN CN201280054639.7A patent/CN103930426B/zh active Active
- 2012-11-05 MX MX2014005184A patent/MX342309B/es active IP Right Grant
- 2012-11-05 CA CA2850458A patent/CA2850458C/en active Active
- 2012-11-05 DK DK12780208.0T patent/DK2776442T3/en active
- 2012-11-05 AU AU2012334173A patent/AU2012334173B2/en active Active
- 2012-11-05 KR KR1020147015045A patent/KR102032337B1/ko active IP Right Grant
- 2012-11-05 JP JP2014540410A patent/JP6138141B2/ja active Active
- 2012-11-05 HU HUE12780208A patent/HUE025543T2/en unknown
- 2012-11-05 EP EP12780208.0A patent/EP2776442B1/en active Active
- 2012-11-05 PL PL12780208T patent/PL2776442T3/pl unknown
- 2012-11-06 AR ARP120104159A patent/AR088663A1/es active IP Right Grant
- 2012-11-06 US US13/669,610 patent/US8741906B2/en active Active
- 2012-11-07 TW TW106134768A patent/TWI704150B/zh active
- 2012-11-07 TW TW101141431A patent/TWI639600B/zh active
-
2014
- 2014-03-28 CO CO14067070A patent/CO6920295A2/es active IP Right Grant
- 2014-04-03 IL IL231949A patent/IL231949A/en active IP Right Grant
- 2014-04-11 US US14/250,781 patent/US9056866B2/en active Active
- 2014-04-22 ZA ZA2014/02905A patent/ZA201402905B/en unknown
- 2014-05-06 CL CL2014001174A patent/CL2014001174A1/es unknown
- 2014-08-06 HK HK14108045.2A patent/HK1194732A1/zh unknown
-
2016
- 2016-01-15 HR HRP20160052TT patent/HRP20160052T1/hr unknown
- 2016-01-19 CY CY20161100050T patent/CY1117147T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI2776442T1 (sl) | Derivati (1,2,3)triazolo(4,5-d)pirimidina kot agonisti kanabinoidnega receptorja 2 | |
SI2782915T1 (sl) | Derivati (1,2,3)triazolo(4,5-d)pirimidina kot agonisti agonistov kanabinoidnega receptorja 2 | |
HRP20190361T1 (hr) | Derivati triazolo[4,5-d]pirimidina kao antagonisti cb2 receptora | |
HK1213559A1 (zh) | 作為 受體激動劑的吡咯並 嘧啶衍生物 | |
ZA201701814B (en) | Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2 | |
ZA201406323B (en) | Triazolo[4,5-d]pyrimidine derivatives | |
PT2694513E (pt) | Derivados de pirazolopirimidina |